DNER and neoplasm: Five drug combinations were common to both tumor derived and experimentally derived SL pairs, of which 2 were synergistic: Navitoclax + I-BET and navitoclax + JQ1, that are mapping on the same targets (I-BET and JQ1 are both BRD targeting drugs).